
Regeneron Pharmaceuticals, Inc. / Financial strength (Piotroski F-Value) /
The F-Value, developed by Stanford accounting professor Joseph Piotroski, measures a company's financial strength based on nine distinct criteria. Piotroski suggest using the value as part of a value investing strategy to rank stocks with a low price-to-book ratio. The approach is described in detail in Piotroski's 2002 Paper Value Investing: The Use of Historical Financial Statement Information to Separate Winners From Losers.
You are viewing the F-Value as of . Click to view the current F-Value instead.
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Return on assets (ROA) greater than 0
- check 13.9%
- Operating cash flow greater than 0
- check $3.65B
- ROA greater than previous year
- close 13.9% ≤ 30.1%
- Cash flow return on assets (CFROA) greater than Return on assets (ROA)
- check 14.2% > 13.9%
- Leverage ratio lower than previous year
- check 9.0% < 10.2%
- Current ratio greater than previous year
- check 545.4% > 475.7%
- No new common stock issued last year
- close $1.27B
- Gross margin greater than previous year
- check 87.0% > 84.6%
- Asset turnover greater than previous year
- close 41.2% ≤ 62.7%
F-Value history
The F-Value is calculated for each quarter based on the cumulation of the previous four quarterly statements. Click on the chart to see the F-Value at a specific time in the past.
-
4
-
4
-
4
-
4
-
3
-
3
-
2
-
4
-
4
-
5
-
4
-
3
-
2
-
5
-
3
-
4
-
4
-
4
-
4
-
4
-
4
-
5
-
5
-
4
-
4
-
4
-
2
-
2
-
2
-
4
-
2
-
5
-
5
-
4
-
4
-
3
-
3
-
2
-
1
-
2
-
2
-
2
-
3
-
3
-
5
-
5
-
5
-
8
-
5
-
5
-
4
-
2
-
2
-
1
-
1
-
2
-
1
-
6
-
5
-
5
-
5
-
6
-
6
-
6
-
5
-
2
-
3
-
1
-
3
-
2
-
4
-
4
-
4
-
4
-
4
-
4
-
4
-
1
-
1
-
3
-
4
-
5
-
6
-
6
-
6
-
5
-
5
-
4
-
4
-
6
-
5
-
5
-
6
-
7
-
6
-
5
-
7
-
6
-
5
-
6
-
4
-
5
-
7
-
6
-
6
-
6
-
6
-
4
-
4
-
5
-
3
-
6
-
3
-
3
-
4
-
5
-
5
-
6
-
7
-
4
-
4
-
4
-
6
-
6
-
5
-
5
-
5
-
3
-
5
-
4
-
4
-
4